<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00759226</url>
  </required_header>
  <id_info>
    <org_study_id>CONKO-101</org_study_id>
    <nct_id>NCT00759226</nct_id>
  </id_info>
  <brief_title>Chemotherapeutic Trial With Gemcitabine, Cisplatin, 5-FU and Folinic Acid in Esophageal Cancer</brief_title>
  <acronym>CONKO-101</acronym>
  <official_title>An Open Labeled Phase 2 Study of Gemcitabine in Combination With Cisplatin, 5-FU (24h CI) and Folinic Acid in Patients With Inoperable Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CONKO-Studiengruppe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CONKO-Studiengruppe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter open labeled phase 2 trial examines the efficacy of a combination of
      Gemcitabine 1000 mg/m2 (30 min), Cisplatin 30 mg/m2 (90 min), Folinic Acid 200 mg/m2 (30 min)
      and 5-FU 750 mg/m2 (24h CI) all given day 1,8 q D22 in patients with inoperable esophageal
      cancer. The combination was considered to be suitable for further evaluation with a freedom
      of progression rate (PR+CR+SD) of more than 60% and not be be of further interest with a rate
      of less than 40%. Given an alpha error of 5% and an beta error of 10% at least 66 evaluable
      patients were needed based on a 2-Stage Simon design with a first evaluation after 25
      evaluable patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint rate of freedom of progression (PR+CR+SD).</measure>
    <time_frame>Max. 8 cycles of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoint median survival, progression free survival and toxicity.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">92</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m2 (30 min)</description>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin 30 mg/m2 (90 min)</description>
    <other_name>Cisplatin medac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>5-FU 750 mg/m2 (24h CI)</description>
    <other_name>5-FU medac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>Folinic Acid 200 mg/m2 (30 min)</description>
    <other_name>Rescuvolin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;=18

          -  Histologically proven inoperable esophageal cancer

          -  Karnofsky Performance status &gt;=60%

          -  Estimated life expectancy of &gt; 12 weeks

          -  Measurable disease

          -  No other oncologic therapy

          -  Measurable disease

          -  Adequate bone marrow function

          -  Geographic proximity and compliance

          -  Informed consent

          -  Negative pregnancy test and adequate contraception

        Exclusion Criteria:

          -  Insufficient hepatic or renal function

          -  Elevated serum calcium

          -  Pregnancy/breast feeding

          -  Active infection

          -  Other malignancies

          -  Systemic tumour complications requiring emergency interventions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanno Riess, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Universitätsmedizin Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2008</study_first_submitted>
  <study_first_submitted_qc>September 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>September 25, 2008</last_update_submitted>
  <last_update_submitted_qc>September 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Hanno Riess, Dr. Helmut Oettle</name_title>
    <organization>Charite Universitätsmedizin Berlin</organization>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>5-FU</keyword>
  <keyword>Folinic Acid</keyword>
  <keyword>inoperable esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

